SCHEMBL6509980

SCHEMBL6509980

[CH2]COc1ccc(-c2n[nH]c3ccc(-c4ncn[nH]4)cc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 4/20 0.53
PRKD3 O94806 2/20 0.53
MAP4K4 O95819 2/20 0.53
MAPK9 P45984 2/20 0.53
CSNK1D P48730 2/20 0.53
CLK2 P49760 2/20 0.53
CSNK1G2 P78368 2/20 0.53
DYRK1A Q13627 2/20 0.53
MELK Q14680 2/20 0.53
PRKD2 Q9BZL6 2/20 0.53
CLK4 Q9HAZ1 2/20 0.53
JAK2 O60674 2/20 0.53
GAK O14976 1/20 0.53
DYRK3 O43781 1/20 0.53
NQO2 P16083 1/20 0.53
CSNK2A2 P19784 1/20 0.53
FECH P22830 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
CSNK1A1 P48729 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5386179 0.85 GSK3B (0.52) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL5377799 0.82 CLK2 (0.53) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL8365703 0.81 MKNK1 (0.60) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL5372567 0.80 ENPP2 (0.51) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL5380918 0.80 MAP2K4 (0.58) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL599945 0.80 MAP3K5 (0.50) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL14514437 0.80 MAP2K4 (0.55) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL7532858 0.79 MAPK8 (0.71) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL5379398 0.77 MAP3K5 (0.66) MAPK8PRKD3MAP4K4MAPK9CSNK1D
SCHEMBL5386487 0.77 MAP4K4 (0.47) MAPK8PRKD3MAP4K4MAPK9CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 MAPK8 25/4885PRKD3 70/4885MAP4K4 41/4885
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R MAPK8 91/4885PRKD3 152/4885MAP4K4 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.